Firms Target Insulin Market Pharmaceuticals: A biosimilar nears approval as MannKind takes a shot at inhalable powder

 

 

MannKind says its compact inhaler can succeed in the insulin market.

Credit: Mannkind

read

 http://cen.acs.org/articles/92/i27/Firms-Target-Insulin-Market.html

Firms Target Insulin Market

Pharmaceuticals: A biosimilar nears approval as MannKind takes a shot at inhalable powder.

Two novel products are being launched to compete in the $21 billion-per-year global insulin market.

A review committee of the European Medicines Agency has recommended approval of an investigational insulin compound developed jointly by Eli Lilly & Co. and Boehringer Ingelheim that would be the first biosimilar version of long-acting insulin sold in Europe.